BC-7013 is a novel semi-synthetic pleuromutilin derivative. BC-7013 has excellent activity against Gram-positive pathogenic bacteria. BC-7013 exhibits potent antibacterial properties against both Staphylococcus, Streptococcus and penicillin-resistant Streptococcus pneumoniae. BC-7013 has activity against Gram-positive pathogenic bacteria, BC-7013 is useful in the research of acute bacterial skin and skin structure infection (ABSSSI).
BC-7013 shows strong inhibitory activity against 303 tested S. aureus isolates with a MIC50 value of 0.015 µg/mL[2].
BC-7013 exhibits potent activity against group A streptococci and group B streptococci with MIC90s values of 0.03 µg/mL and 0.06 µg/mL, respectively[2].
References:
[1]. Shang R, et al. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem. 2013;13(24):3013-25.
[2]. Biedenbach D J, et al. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009, 49: 199